- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04238728
Silverlon to Reduce Radiation Dermatitis
An Unblinded, Open-label Study Evaluating the Safety of Silverlon to Manage Radiation Dermatitis.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- Wilmot Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Females, 22 years of age or older, with diagnosis of primary breast cancer (excluding inflammatory and medullary breast cancers).
- Scheduled to receive short-course external beam radiation therapy (i.e., 2.0-3.0 Gy for 15-20 fractions) or conventional external beam radiation therapy (i.e., 1.8-2.0 Gy for 25-40 fractions), with or without boost dose, to the whole breast.
- Not receiving concurrent chemotherapy.
- Subject may have had chemotherapy prior to radiation. A minimum of two weeks is required between the end of chemotherapy and start of radiation therapy.
- No history of previous breast or chest radiation therapy.
- Subject may or may not have had surgery (lumpectomy or mastectomy) prior to RT. (Note: Surgery is not required for eligibility).
- Subjects may be currently prescribed hormone treatment or Herceptin therapy.
- Subjects must be able to read, speak, and understand English language (all study forms are in English).
- Subjects must be able to give informed consent.
- Subjects must be willing to have photographs taken of radiation-induced skin changes in the radiation treatment area.
- Subjects must be willing to wear Silverlon dressing and undergarment (i.e., bra) at all times, except when bathing/showering and during their radiation therapy session.
- Subjects must be willing to complete a Silverlon Compliance Log to document the date and time that Silverlon was removed and applied each day during the study.
Exclusion Criteria:
- Diagnosis of medullary or inflammatory breast cancer.
- Diagnosis of tumors of the breast other than primary breast cancer (skin cancers, lymphomas, or metastatic cancers from other primary sites).
- Partial breast irradiation (PBI) treatment technique is not eligible.
- Concurrent chemotherapy.
- Pregnant or planning to become pregnant. Pregnant females are ineligible because pregnancy is a contraindication for RT. All subjects of childbearing potential will be asked if they are pregnant or could be pregnant. The subject must respond "no" to continue with radiation and to participate in this clinical study.
- Previous radiation to the chest or breast.
- Radiation being given for palliative purposes.
- Presence of unhealed surgical wounds, biopsy sites, open wounds in the breast or chest area.
- Presence of breast infection.
- Subjects currently on anti-EGFR (human epidermal growth factor receptor) therapy, such as Iressa (gefitinib) or Erbitux (cetuximab, C225).
- Previous diagnosis of autoimmune disease, connective tissue disease, or radiosensitivity disorder.
- Presence of any active dermatological issues in radiation treatment area (i.e., fungal skin infection, dermatitis, psoriasis plaques, etc).
- Chronic skin disease of the breast, previous breast trauma or scarring of the breast
- Subjects with known sensitivity to silver or nylon.
- Subjects unable or unwilling to wear Silverlon dressings and undergarment (i.e., bra) at all times, except while bathing/showering and during their radiation therapy session.
- Subjects unable to speak, read, or understand English language (all study forms are in English).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Silverlon arm
Silverlon is a silver-nylon dressing approved for treatment of burns and wounds.
In this study, the Silverlon dressing will be applied to the whole breast area receiving radiation therapy throughout the prescribed course of radiation therapy starting the first day of radiation therapy and until two weeks post-radiation.
The Silverlon dressing will be held in place by a bra and worn daily except when bathing/showering, received radiation therapy, or swimming.
Subject document when they remove the dressing and apply the dressing every day.
|
silver nylon dressing will be applied daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With an Adverse Skin Event
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Each Grade of the Radiation Therapy Oncology Group (RTOG) Toxicity Score
Time Frame: 2 weeks
|
The radiation oncologist or nurse will rate the skin reaction in the area where Silverlon dressing was applied using the RTOG scale which ranges from 0-5 with higher scores indicating worse outcome. Grade 0 No change; Normal Skin Grade 1 Faint erythema; dry desquamation; epilation, decreased sweating Grade 2 Tender or bright erythema; moderate edema; patchy moist desquamation only in skin folds. Grade 3 Confluent moist desquamation in areas other than skin folds; pitting edema Grade 4 Ulceration; hemorrhage; necrosis |
2 weeks
|
Mean Radiation Induced Skin Reaction Assessment Scale
Time Frame: Mid study-visit, approximately 2 weeks
|
This scoring system contains both a healthcare professions assessment scale and a patient symptom scale.
The healthcare professional assessment scale (HPAS) individually scores the extent and severity of erythema, dry desquamation, moist desquamation, and necrosis using a 5-point scale from 0 to 4. Erythema is rated based on the degree of color change.
Dry desquamation, moist desquamation, and necrosis are rated based on the percentage of the treatment area affected by that particular reaction.
The HPAS score can range between 0 to 16.
The patient symptom scale focuses on skin tenderness, itching, burning, and functional activity using a 4-point scale from 1 to 4. The patient symptom scale can range between 4 to 16.
The Healthcare Professional Assessment Scale scores and the Patient Symptom Scale scores are added together for a total skin reaction score.
The total skin reaction score can range between 4 to 32.
The higher the score, the worse the skin reaction.
|
Mid study-visit, approximately 2 weeks
|
Mean Radiation Induced Skin Reaction Assessment Scale
Time Frame: End of radiation therapy, approximately 4.5 weeks
|
This scoring system contains both a healthcare professions assessment scale and a patient symptom scale.
The healthcare professional assessment scale (HAPS) individually scores the extent and severity of erythema, dry desquamation, moist desquamation, and necrosis using a 5-point scale from 0 to 4. Erythema is rated based on the degree of color change.
Dry desquamation, moist desquamation, and necrosis are rated based on the percentage of the treatment area affected by that particular reaction.
The HPAS score can range between 0 to 16.
The patient symptom scale focuses on skin tenderness, itching, burning, and functional activity using a 4-point scale from 1 to 4. The patient symptom scale can range between 4 to 16.
The Healthcare Professional Assessment Scale scores and the Patient Symptom Scale scores are added together for a total skin reaction score.
The total skin reaction score can range between 4 to 32.
The higher the score, the worse the skin reaction.
|
End of radiation therapy, approximately 4.5 weeks
|
Mean Radiation Induced Skin Reaction Assessment Scale
Time Frame: 2 weeks post radiation therapy, approximately 6.5 weeks
|
This scoring system contains both a healthcare professions assessment scale and a patient symptom scale.
The healthcare professional assessment scale (HPAS) individually scores the extent and severity of erythema, dry desquamation, moist desquamation, and necrosis using a 5-point scale from 0 to 4. Erythema is rated based on the degree of color change.
Dry desquamation, moist desquamation, and necrosis are rated based on the percentage of the treatment area affected by that particular reaction.
The HPAS score can range between 0 to 16.
The patient symptom scale focuses on skin tenderness, itching, burning, and functional activity using a 4-point scale from 1 to 4. The patient symptom scale can range between 4 to 16.
The Healthcare Professional Assessment Scale scores and the Patient Symptom Scale scores are added together for a total skin reaction score.
The total skin reaction score can range between 4 to 32.
The higher the score, the worse the skin reaction.
|
2 weeks post radiation therapy, approximately 6.5 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00004587
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Radiation Dermatitis
-
Chang Gung Memorial HospitalNot yet recruiting
-
German University in CairoAin Shams UniversityCompleted
-
China Medical University HospitalCompletedRadiation DermatitisTaiwan
-
Sheba Medical CenterFerring PharmaceuticalsCompleted
-
Apeiron BiologicsCompleted
-
Lutris Pharma Ltd.CompletedRadiation DermatitisUnited States
-
University of RochesterNational Cancer Institute (NCI)CompletedRadiation-induced Dermatitis
-
University of the PhilippinesRecruitingAcute Radiation DermatitisPhilippines
-
China Medical University HospitalNot yet recruitingBreast Cancer | Radiation Dermatitis
-
Pharm Olam Pharmaceuticals Ltd.UnknownPrevention of Radiation Induced Dermatitis.
Clinical Trials on Silverlon
-
United States Army Institute of Surgical ResearchCompleted
-
University of MichiganCura SurgicalTerminatedObesity | Complications; Caesarean Section, WoundUnited States
-
Jorge MarcetCompletedInfections | SurgeryUnited States
-
United States Army Institute of Surgical ResearchSamueli Institute for Information BiologyCompleted
-
University of South FloridaCompletedSurgical Site Infection | Post Operative Pain | Cosmetic Appearance of Cesarean ScarUnited States
-
University of California, San FranciscoInternational Consortium of Circulatory Assist CliniciansRecruitingLVAD (Left Ventricular Assist Device) Driveline InfectionUnited States
-
Alpine Immune Sciences, Inc.Active, not recruitingSystemic Lupus ErythematosusUnited States, France, Hungary, Poland, Puerto Rico, Spain, Taiwan
-
Kansas City Heart Rhythm InstituteCompletedWounds and Injuries | InfectionsUnited States